Dr. Jeremy Levin | Source | Chairman Of The Board at Opthea

We have the capital, the expert team and the right strategy in place to unlock value in the rapidly growing field of rare neurology. With the perspectives of renowned biotech leaders who have recently joined our board and advisory team, we believe Ovid has the knowledge and access to pursue differentiated technologies and medicines for the brain.

Waiting increases the probability that the immunity gained by the original vaccination will diminish.

Greenwood’s leadership in the industry has allowed the United States to create a pro-innovation public policy environment that has become the envy of the world. Over the course of the next year-and-a-half that Greenwood will remain with BIO. The organization will continue to depend on his leadership as the industry fights short-sighted attempts to drain capital from our sector and curtail the intellectual property rights of innovators.